CMBA
AMPH icon

C.M. Bidwell & Associates’s Amphastar Pharmaceuticals AMPH Stock Holding History

C.M. Bidwell & Associates’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-65
Closed -$2K – 478
2022
Q2 		$2K Buy
+65
New +$2.32K ﹤0.01% 427
2017
Q1 		– Sell
-9,735
Closed -$179K – 220
2016
Q4 		$179K Sell
9,735
-2,960
-23% -$57.6K 0.04% 173
2016
Q3 		$241K Sell
12,695
-125
-1% -$2.27K 0.06% 146
2016
Q2 		$207K Buy
+12,820
New +$181K 0.05% 141

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

C.M. Bidwell & Associates's AMPH Position: Q3 2022 in Review

C.M. Bidwell & Associates sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2022, closing a stake of 65 shares — an estimated $2K sold.

C.M. Bidwell & Associates first reported a position in AMPH in Q2 2016 and held it in 4 quarters. The position peaked at $241K in Q3 2016. 205 funds tracked by Wall St. Rank hold AMPH as of Q3 2022.

  • C.M. Bidwell & Associates reported no remaining Amphastar Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 65 Amphastar Pharmaceuticals shares in Q3 2022, an estimated $2K.
  • C.M. Bidwell & Associates first reported a position in Amphastar Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • C.M. Bidwell & Associates's Amphastar Pharmaceuticals position peaked at $241K in Q3 2016.
  • 205 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2022, filed 14 Nov 2022.